What is ImpriMed?
Founded in 2017 and headquartered in Palo Alto, California, ImpriMed operates at the intersection of biotechnology and veterinary medicine. The company specializes in analyzing live cancer cells from pet patients to gather critical systemic information. This data-driven approach aims to provide veterinarians and pet owners with more precise insights into cancer progression and treatment efficacy, potentially revolutionizing how cancer is managed in companion animals. The company's technology offers a novel method for understanding the unique biological characteristics of each tumor.
How much funding has ImpriMed raised?
ImpriMed has raised a total of $31M across 2 funding rounds:
Other Financing Round
$8M
Series A
$23M
Other Financing Round (2021): $8M with participation from Primer Sazze Partners, BonAngels, Translink Investment, Draper Associates, Futureplay, Murex Partners, E.S. Investments, HG Initiative, and Draper Dragon
Series A (2023): $23M led by Samyang Chemical Group (삼양화학그룹, Byucksan, SK Telecom, and Murex Partners
Key Investors in ImpriMed
Samyang Chemical Group (삼양화학그룹
Samyang Chemical Group is a diversified conglomerate with interests in chemicals, distribution, steel, and real estate, actively investing in promising startups through its DREAUM initiative to drive innovation.
SK Telecom
SK Telecom is a leading South Korean telecommunications company specializing in 5G networks, AI solutions, and digital infrastructure, with a strategic interest in innovative technology ventures.
Draper Associates
Draper Associates is a prominent venture capital firm known for backing early-stage technology companies with the potential to disrupt global industries.
What's next for ImpriMed?
With the recent influx of major strategic capital, ImpriMed is poised for significant expansion and further development of its diagnostic capabilities. This enterprise-level funding is expected to accelerate research and development efforts, enhance its operational infrastructure, and broaden its market reach within the veterinary oncology sector. The company's strategic focus will likely involve refining its analytical platforms and forging partnerships to integrate its findings into standard veterinary care protocols, ultimately aiming to improve treatment outcomes for pets battling cancer.
See full ImpriMed company page
